Literature DB >> 30803229

Development of Highly Potent, Selective, and Cellular Active Triazolo[1,5- a]pyrimidine-Based Inhibitors Targeting the DCN1-UBC12 Protein-Protein Interaction.

Shuai Wang1,2,3, Lijie Zhao1,2,3, Xiao-Jing Shi1,2,3, Lina Ding1,2,3, Linlin Yang4, Zhi-Zheng Wang1,2,3, Dandan Shen1,2,3, Kai Tang1,2,3, Xiao-Jing Li1,2,3, Maa Mamun1,2,3, Huiju Li1,2,3, Bin Yu1,2,3,5, Yi-Chao Zheng1,2,3, Shaomeng Wang1,6, Hong-Min Liu1,2,3.   

Abstract

The cullin-RING ubiquitin ligases (CRLs) are responsible for about 20% of cellular protein degradation and regulate diverse cellular processes, and the dysfunction of CRLs is implicated in human diseases. Targeting the CRLs has become an emerging strategy for the treatment of human diseases. Herein, we describe the discovery of a hit compound from our in-house library and further structure-based optimizations, which have enabled the identification of new triazolo[1,5- a]pyrimidine-based inhibitors targeting the DCN1-UBC12 interaction. Compound WS-383 blocks the DCN1-UBC12 interaction (IC50 = 11 nM) reversibly and shows selectivity over selected kinases. WS-383 exhibits cellular target engagement to DCN1 in MGC-803 cells. WS-383 inhibits Cul3/1 neddylation selectively over other cullins and also induces accumulation of p21, p27, and NRF2. Collectively, targeting the DCN1-UBC12 interaction would be a viable strategy for selective neddylation inhibition of Cul3/1 and may be of therapeutic potential for disease treatment in which Cul3/1 is dysregulated.

Entities:  

Year:  2019        PMID: 30803229     DOI: 10.1021/acs.jmedchem.9b00113

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  Discovery of Novel Pyrazolo-pyridone DCN1 Inhibitors Controlling Cullin Neddylation.

Authors:  Ho Shin Kim; Jared T Hammill; Daniel C Scott; Yizhe Chen; Jaeki Min; Jonah Rector; Bhuvanesh Singh; Brenda A Schulman; R Kiplin Guy
Journal:  J Med Chem       Date:  2019-09-13       Impact factor: 7.446

Review 2.  Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment.

Authors:  Wen Li; Feifei Li; Xia Zhang; Hui-Kuan Lin; Chuan Xu
Journal:  Signal Transduct Target Ther       Date:  2021-12-20

3.  Improvement of Oral Bioavailability of Pyrazolo-Pyridone Inhibitors of the Interaction of DCN1/2 and UBE2M.

Authors:  Ho Shin Kim; Jared T Hammill; Daniel C Scott; Yizhe Chen; Amy L Rice; William Pistel; Bhuvanesh Singh; Brenda A Schulman; R Kiplin Guy
Journal:  J Med Chem       Date:  2021-05-04       Impact factor: 7.446

4.  Selective inhibition of cullin 3 neddylation through covalent targeting DCN1 protects mice from acetaminophen-induced liver toxicity.

Authors:  Haibin Zhou; Jianfeng Lu; Krishnapriya Chinnaswamy; Jeanne A Stuckey; Liu Liu; Donna McEachern; Chao-Yie Yang; Denzil Bernard; Hong Shen; Liangyou Rui; Yi Sun; Shaomeng Wang
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

5.  Drug repurposing: Discovery of troxipide analogs as potent antitumor agents.

Authors:  Nan Lu; Jin-Ling Huo; Shuai Wang; Xiao-Han Yuan; Hong-Min Liu
Journal:  Eur J Med Chem       Date:  2020-06-26       Impact factor: 6.514

Review 6.  Anticancer drug discovery by targeting cullin neddylation.

Authors:  Qing Yu; Yihan Jiang; Yi Sun
Journal:  Acta Pharm Sin B       Date:  2019-09-20       Impact factor: 11.413

Review 7.  Targeting neddylation E2s: a novel therapeutic strategy in cancer.

Authors:  Yi-Chao Zheng; Yan-Jia Guo; Bo Wang; Chong Wang; M A A Mamun; Ya Gao; Hong-Min Liu
Journal:  J Hematol Oncol       Date:  2021-04-07       Impact factor: 17.388

Review 8.  [Targeting Cullin-RING E3 ligases for anti-cancer therapy: efforts on drug discovery].

Authors:  Qing Yu; Xiufang Xiong; Yi Sun
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-05-25

9.  Gossypol inhibits cullin neddylation by targeting SAG-CUL5 and RBX1-CUL1 complexes.

Authors:  Qing Yu; Zhiguo Hu; Yanwen Shen; Yihan Jiang; Peichen Pan; Tingjun Hou; Zhen-Qiang Pan; Jing Huang; Yi Sun
Journal:  Neoplasia       Date:  2020-04       Impact factor: 5.715

10.  Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor.

Authors:  Pengxing He; Shenghui Niu; Shuai Wang; Xiaojing Shi; Siqi Feng; Linna Du; Xuyang Zhang; Zhilu Ma; Bin Yu; Hongmin Liu
Journal:  Acta Pharm Sin B       Date:  2019-06-28       Impact factor: 11.413

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.